Anticholinergic News and Research

RSS

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Antares Pharma, Inc. announced today positive results from its Phase 3 study of Anturol Gel in patients with overactive bladder. The study met its primary endpoint of a statistically significant reduction in urinary incontinence episodes for both doses studied.

28 Jul 2010

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that detailed results from two Phase 3 clinical trials of the company's product Silenor® (doxepin) have been accepted for publication in peer-reviewed scientific journals.

22 Jul 2010

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Drugs commonly taken for a variety of common medical conditions including insomnia, allergies, or incontinence negatively affect the brain causing long term cognitive impairment in older African-Americans, according to a study appearing in the July 13, 2010 print issue of Neurology, the medical journal of the American Academy of Neurology.

14 Jul 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

Light sedation decreases postoperative delirium in elderly patients by 50%

A recent study, published in the January issue of Mayo Clinic Proceedings, demonstrates that in elderly patients undergoing hip fracture repair under spinal anesthesia with propofol sedation, the prevalence of delirium can be decreased by 50 percent with light sedation, compared to deep sedation.

20 Jan 2010

Lighter sedation during spinal anesthesia reduces postoperative delirium in elderly patients

19 Jan 2010

PIMs usage among elderly patients may increase adverse events and health care costs

A new study provides important evidence that the use of certain potentially inappropriate medications (PIMs) among the elderly may increase adverse events and health care costs.

13 Jan 2010

January issue of Chest presents new studies on COPD

A new study shows that poor lung function during adolescence and through midlife may be influenced by several factors, including birth weight, height, and gender.

5 Jan 2010

Allergan reports operating results for the third quarter of 2009

Allergan, Inc. today announced operating results for the quarter ended September 30, 2009. Allergan also announced that its Board of Directors has declared a third quarter dividend of $0.05 per share, payable on November 30, 2009 to stockholders of record on November 9, 2009.

29 Oct 2009

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Uroplasty, Inc., a medical device company developing, manufacturing and marketing innovative proprietary products for the treatment of voiding dysfunctions, today highlighted presentations, workshops and posters focused on its products at the 39th Annual Meeting of the International Continence Society Meeting (ICS), September 29 - October 3 in San Francisco.

7 Oct 2009

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Quintiles Transnational Corp. and Allergan, Inc. (NYSE: AGN) today announced an agreement under which Quintiles will co-promote Allergan's SANCTURA XR® (trospium chloride extended release capsules), an anticholinergic approved for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency, predominantly to primary care physicians in the United States.

28 Sep 2009

Botox injections can help overactive bladders sufferers

Botox is well known for its cosmetic uses, but researchers have now found that it can also significantly improve people's quality of life if they suffer from another problem that increases with age, an overactive bladder (OAB).

9 Jun 2009

Commonly used medications may produce cognitive impairment in seniors

Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults according to a clinical review now available online in the Journal of Clinical Interventions in Aging, a peer reviewed, open access publication.

1 Jun 2009

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Merck Serono announced today the initiation of the SETTLE study. This study will evaluate the efficacy and safety of a dose range of safinamide (50-100 mg once daily) as add-on therapy to a stable dose of levodopa, in mid- to late-stage Parkinson's disease patients with motor fluctuations compared to placebo.

7 May 2009

Anticholinergic medications linked to cognitive decline in seniors

A study published in Journal of the American Geriatrics Society suggested that the use of certain medications in elderly populations may be associated with cognitive decline.

27 Jan 2009

Popular COPD treatment increases risk for cardiac events, cardiac death

New research out of Wake Forest University School of Medicine shows that use of the most commonly prescribed once-a-day treatment for chronic obstructive pulmonary disease (COPD) for longer than one month increases the risk of cardiovascular death, heart attack or stroke by more than 50 percent

24 Sep 2008

Dual treatment of incontinence and dementia associated with functional decline

Older nursing home residents who took medications for dementia and incontinence at the same time had a 50 percent faster decline in function than those who were being treated only for dementia, according to a study from researchers at Wake Forest University School of Medicine and colleagues.

1 May 2008

Alzheimer's disease risk differs between the sexes

The risks of developing Alzheimer's disease differ between the sexes, with stroke in men, and depression in women, critical factors, suggests research published ahead of print in the Journal of Neurology Neurosurgery and Psychiatry.

30 Apr 2008

Dual treatment of incontinence and dementia associated with functional decline

30 Apr 2008

Anti-cholinergic drugs may increase cognitive decline in older people

Anticholinergic drugs, such as medicines for stomach cramps, ulcers, motion sickness, and urinary incontinence, may cause older people to experience greater decline in their thinking skills than people not taking the drugs, according to research that will be presented at the American Academy of Neurology 60th Anniversary Annual Meeting in Chicago, April 12–19, 2008.

17 Apr 2008

Anticholinergic News and Research

Antares Pharma reports positive results from Anturol Gel Phase 3 study in overactive bladder patients

Somaxon's Silenor Phase 3 clinical data accepted for publication in Sleep, Sleep Medicine journals

Drugs taken for common medical conditions cause long term cognitive impairment in older adults: Study

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Light sedation decreases postoperative delirium in elderly patients by 50%

Lighter sedation during spinal anesthesia reduces postoperative delirium in elderly patients

PIMs usage among elderly patients may increase adverse events and health care costs

January issue of Chest presents new studies on COPD

Allergan reports operating results for the third quarter of 2009

Uroplasty's Urgent PC and Macroplastique presented at the International Continence Society Meeting

Quintiles Transnational enter into marketing agreement with Allergan for SANCTURA XR

Botox injections can help overactive bladders sufferers

Commonly used medications may produce cognitive impairment in seniors

Merck Serono starts second phase III trial of Safinamide in advanced Parkinson's

Anticholinergic medications linked to cognitive decline in seniors

Popular COPD treatment increases risk for cardiac events, cardiac death

Dual treatment of incontinence and dementia associated with functional decline

Alzheimer's disease risk differs between the sexes

Dual treatment of incontinence and dementia associated with functional decline

Anti-cholinergic drugs may increase cognitive decline in older people

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News